Nilotinib Clinical Trials

4 actively recruiting trials across 2 locations

▼ -1 trial since June 2026

Also known as: AMN107, TASIGNA, Tasigna

Pipeline

Phase 2: 3Phase 4: 1

Top Sponsors

The Netherlands Cancer Institute1
Novartis Pharmaceuticals1
Medical College of Wisconsin1
Gruppo Italiano Malattie EMatologiche dell'Adulto1

Indications

Cancer4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive1
Neoplasia1
Tumors1
Chronic Myeloid Leukemia, BCR/ABL-Positive1

Other2 trials

PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

Phase 2

The Drug Rediscovery Protocol (DRUP Trial)

Phase 2

Ann Arbor, Michigan1 trial

Asciminib Roll-over Study

Michigan Med University of Michigan

Phase 4

Detroit, Michigan1 trial

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

The Barbara Ann Karmanos Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.